New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2014
09:59 EDTTWTR, BIDU, BP, APOL, QCOR, MRK, PCLN, MCPActive equity options trading on open
Active equity options trading on open according to Track Data: BP BIDU APOL PG QCOR MRK TWTR PCLN GMCR MCP AAPL
News For TWTR;BIDU;BP;APOL;QCOR;MRK;PCLN;MCP From The Last 14 Days
Check below for free stories on TWTR;BIDU;BP;APOL;QCOR;MRK;PCLN;MCP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 14, 2014
05:54 EDTBPBP upgraded to Buy from Hold at Canaccord
Subscribe for More Information
05:54 EDTQCORStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 44, MannKind (MNKD) 83 according to iVolatility.
April 11, 2014
12:44 EDTPCLN, TWTR, BIDUHedge funds initiating shorts on Priceline, Amazon, Twitter, CNBC says
Subscribe for More Information
10:46 EDTQCOROptions with decreasing implied volatility: MNKD QCOR NQ WWE BBBY
10:10 EDTTWTRTwitter bounces, drops, heads for retest of session lows
Subscribe for More Information
09:37 EDTTWTRActive equity options trading on open
Subscribe for More Information
08:11 EDTBPBP says can help improve relations between west, Russia, Reuters says
In an effort to calm shareholders' worries over the company's large exposure to Russia, BP executives said it can help improve relations between Russia and the west and is talking to politicians all over the globe, according to Reuters, citing comments from CEO Bob Dudley. Reference Link
06:04 EDTQCORStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
11:44 EDTPCLNStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:03 EDTQCOROptions with decreasing implied volatility: MNKD QCOR MU KMX
10:00 EDTTWTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:38 EDTPCLNExpedia bookings growth potential being overlooked, says FBR Capital
Subscribe for More Information
06:33 EDTTWTRTwitter upgraded to Hold from Sell at Cantor
Cantor Fitzgerald upgraded its rating on Twitter (TWTR) shares to Hold from Sell citing the recent pullback in the stock as well as the upcoming launch of new ad formats which it believes should drive monetization. Cantor maintains a $45 price target for the stock and says it continues to prefer Facebook (FB). Shares of Twitter closed yesterday up 71c to $42.49.
06:06 EDTQCORStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use